Cannabinod formulation for the sedation of a human or animal
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/352
A61K-045/06
출원번호
US-0820507
(2015-08-06)
등록번호
US-9585867
(2017-03-07)
발명자
/ 주소
Ankner, Charles Everett
출원인 / 주소
Ankner, Charles Everett
대리인 / 주소
The Roy Gross Law Firm, LLC
인용정보
피인용 횟수 :
0인용 특허 :
147
초록▼
A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery system which doses the recipient with the formulation resulting in a tetrahydrocan
A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery system which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood for immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery system to induce an incapacitating or immobilizing dose of the formulation at a distance. Providing a formulation including an antipsychotic to prevent or mitigate any violent psychosis of the recipient. Providing the formulation which induces a lethal cannabinoid blood level in the recipient which causes the death of the recipient within a humane period of time after formulation administration.
대표청구항▼
1. A method of humanely incapacitating a human or animal, the method comprising the steps of: providing a formulation including a cannabinoid;providing a delivery system comprising an injection step for dosing the recipient with the cannabinoid formulation resulting in a tetrahydrocannabinol blood l
1. A method of humanely incapacitating a human or animal, the method comprising the steps of: providing a formulation including a cannabinoid;providing a delivery system comprising an injection step for dosing the recipient with the cannabinoid formulation resulting in a tetrahydrocannabinol blood level in the recipient of greater than one-to-fifty milligrams per milliliter of whole blood (1-50 mg/ml) and below a dosage which causes irreparable harm to or the death of the recipient; andimmobilizing the recipient by using the delivery system to dose the recipient with said formulation. 2. The method of claim 1 wherein the formulation includes at least one dissociative anesthetic from the group consisting of benzodiazepines, barbiturates, opiates, diprivan, and combinations thereof. 3. The method of claim 1 wherein the formulation includes at least one anesthetic gas from the group consisting of benzodiapines, diprivan, thiopental, ketamine, desflurane, isoflurane, nitrous oxide, sevoflurane, xenon, and combinations thereof. 4. The method of claim 1 wherein the formulation includes at least one antipsychotic from the group consisting of antipsychotic or neroleptic formulations including butyrophenones, phenothiazines, thioxanthenes, atypical antipsychotics, second-generation antipsychotics, and combinations thereof. 5. The method of claim 1 wherein the delivery system comprises a hypodermic injection. 6. The method of claim 1 wherein the delivery system comprises a fluid, liquid, semi-solid, or solid. 7. The method of claim 1 wherein the delivery system doses the recipient with the formulation at a distance. 8. A method of humanely incapacitating or immobilizing a human or animal comprising: providing a formulation including a cannabinoid;providing a delivery system comprising an injection step capable of dosing the recipient with the formulation at a distance which renders a recipient incapacitated or immobilized within a short period of time after dosing, and wherein the recipient remains incapacitated or immobilized for a long period of time-after dosing without irreparable harm to or the death of the recipient; andimmobilizing the recipient by using the delivery system to dose the recipient with said formulation. 9. The method of claim 1 wherein the delivery system provides the incapacitating dose of the formulation to the recipient without the recipient's knowledge until the onset of incapacitation of the recipient caused by the formulation. 10. A method of humanely incapacitating a human or animal comprising: providing a formulation including a cannabinoid which renders a recipient incapacitated after administration of the formulation to the recipient;providing a delivery system comprising an injection step which doses the recipient with the formulation inducing a tetrahydrocannabinol blood level of above at least approximately one to two-hundred-and-fifty milligrams per milliliter of whole blood (1-250 mg/ml) and below a dosage which causes irreparable harm to or the death of the recipient; andwherein the formulation continues to render the recipient incapacitated without irreparable harm to or the death of the recipient. 11. The method of claim 1, wherein the formulation includes a cannabinoid emulsified in sesame oil, polysorbate 80 or a saline vehicle. 12. The method of claim 11, wherein the concentration of the cannabinoid in the formulation ranges from 15 mg/ml to 40 mg/ml. 13. The method of claim 1, wherein the amount of the cannabinoid provided to the human or animal ranges from 1.0 mg to 25 mg. 14. The method of claim 1, wherein the amount of the cannabinoid provided to the human or animal ranges from 5.0 mg to 100 mg.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (147)
Lippa,Arnold Stan; Epstein,Joseph William, (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor.
Burstein Sumner H. (6 Knight Rd. Framingham MA 01701) Mechoulam Raphael (Jerusalem ILX), (3R,4R)-D6-tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents an.
Mechoulam Raphael (Jerusalem ILX) Breuer Aviva (Jerusalem ILX) Devane William (Jerusalem ILX) Burstein Sumner H. (Framingham MA), (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceu.
Mechoulam, Raphael; Gallily, Ruth; Breuer, Aviva; Shohami, Esther; Panikashvili, David, 2-arachidonylglycerol (2-AG)-an inhibitor of tumor necrosis factor-α and neuroprotector of brain in closed head injury.
Hale, Ron L.; Lei, Mingzu; Lloyd, Peter M.; Munzar, Patrik; Sharma, Krishnamohan; Solas, Dennis W.; Stracker, Matthew D., Aerosol drug delivery device incorporating percussively activated heat packages.
Fride,Ester; Breuer,Aviva; Hanus,Lumir; Tchilibon,Susanna; Horowitz,Michal; Mechoulam,Raphael; Garzon,Aaron, Agonists specific for the peripheral cannabinoid receptor.
Roques, Bernard; Fournie-Zaluski, Marie-Claude, Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors.
Mittendorf, Joachim; Dressel, Jurgen; Matzke, Michael; Keldenich, Jorg; Mohrs, Klaus-Helmut; Raddatz, Siegfried; Franz, Jurgen; Spreyer, Peter; Vohringer, Verena; Schuhmacher, Joachim; Rock, Michael-, Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases.
Joachim Mittendorf DE; Jurgen Dressel DE; Michael Matzke DE; Jorg Keldenich DE; Frank Mauler DE; Jean-Marie-Victor de Vry DE; Jurgen Franz DE; Peter Spreyer DE; Verena Vohringer DE; Joachim , Aryl sulphonamides and analogues.
McPhillips, Andrea M; Economou, Julia J; Dedhiya, Mahendra G; Wynne, Beverly Ann, Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent.
Whittle, Brian; Javid, Farideh Afshin, Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions.
Mechoulam, Raphael; Kogan, Natalya M.; Rabinowitz, Ruth; Schlesinger, Michael, Compositions including quinonoid derivatives of cannabinoids for therapeutic use.
Putman, David; Hogenkamp, Derk; Dasse, Olivier; Whittemore, Edward R.; Jensen, Mark S., Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use.
Kuliopulos, Athan; Covic, Lidija, G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same.
Park, Joon-Hyun; Apuya, Nestor; Bobzin, Steven Craig, Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations.
McKinney Laurence O. (881 Massachusetts Ave. Cambridge MA 02139), Method and apparatus for processing herbaceous plant materials including the plant cannabis.
Lowenstein, William; Sanchez, Mario; Lepere-Prevot, Benedicte; De Rothschild, Benjamin, Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence.
Letzel, Heinz; Ebell, legal representative, Thomas; Klaeger, Regina; Klaeger, Rudolph, Plant extract from low-THC Cannabis for the treatment of disease.
Razdan Raj Kumar (Belmont MA) Dalzell Haldean Cloyce (Weston MA), Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans.
Whittle, Brian; Guy, Geoffrey; Downs, David; Pate, David, Processes and apparatus for extraction of active substances and enriched extracts from natural products.
Whittle, Brian; Guy, Geoffrey; Downs, David; Pate, David W., Processes and apparatus for extraction of active substances and enriched extracts from natural products.
Stinchcomb, Audra Lynn; Golinski, Miroslaw Jerzy; Hammell, Dana Carmel; Howard, Jeffery Lynn, Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same.
Stinchcomb, Audra Lynn; Golinski, Miroslaw Jerzy; Hammell, Dana Carmel; Howard, Jeffrey Lynn, Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same.
Fliri, Anton Franz Joseph; Butler, Todd William; Gallaschun, Randall James; Ragan, John Anthony; Jones, Brian Patrick, Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof.
Whalley, Ben; Stephens, Gary; Williams, Claire; Guy, Geoffrey; Wright, Stephen; Kikuchi, Tetsuro, Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy.
Peart, Joanne; Byron, Peter R.; Lichtman, Aron H.; Martin, Billy R., Δ9 tetrahydrocannabinol (Δ9 THC) solution metered dose inhalers and methods of use.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.